CytomX Therapeutics, Inc. (CTMX) Q2 FY26 Earnings Call

Year-end Varseta M data is the key near-term catalyst before a planned first pivotal study in first-half 2027. [4]

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-06
Length38 minutes
EPS$-0.09
EPS consensus$-0.11
Revenue$1.4M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All CTMX earnings ยท Back to CTMX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.